SuperworthAnika Therapeutics free cash flow ANIK
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $562K
- Latest quarter, Q2 FY26
- −$2.1M
- Fiscal year 2025
- $4.4M
Anika Therapeutics' free cash flow was $562K over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.1M.
Over the five fiscal years to FY2025 it shrank 18% a year on average.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $4.4M | n/a |
| FY2024 | −$2.3M | n/a |
| FY2023 | −$7.2M | n/a |
| FY2022 | −$3.1M | −195% |
| FY2021 | $3.3M | −72% |
| FY2020 | $11.4M | −67% |
| FY2019 | $34.2M | +13% |
| FY2018 | $30.3M | −5% |
| FY2017 | $31.8M | +205% |
| FY2016 | $10.4M | −65% |
| FY2015 | $29.8M | −27% |
| FY2014 | $40.9M | +65% |
| FY2013 | $24.7M | +173% |
| FY2012 | $9M | +3% |
| FY2011 | $8.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.1M | n/a | $562K | |
| Q1 FY26 | −$6.3M | n/a | $1M | |
| Q4 FY25 | $4M | +1351% | $4.4M | |
| Q3 FY25 | $5M | +31% | $648K | |
| Q2 FY25 | −$1.7M | n/a | −$535K | |
| Q1 FY25 | −$3M | n/a | −$3.4M | |
| Q4 FY24 | $275K | −85% | −$2.3M | |
| Q3 FY24 | $3.8M | −34% | −$808K | |
| Q2 FY24 | −$4.5M | n/a | $1.1M | |
| Q1 FY24 | −$1.9M | n/a | −$4.1M | |
| Q4 FY23 | $1.8M | n/a | −$7.2M | |
| Q3 FY23 | $5.7M | +464% | −$11.1M |
Against its peers
Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| ANIKAnika Therapeutics | 0.2% |
| INFUInfuSystem | 8.3% |
| UTMDUtah Medical Products | 4.8% |
| EMBCEmbecta | n/m |
| PDEXPro DEX | 3.4% |
| TCMDTactile Systems Technology | 5.0% |
| MDXGMimedx | n/m |
| MOVMovado | 10.2% |
| KEQUKewaunee Scientific | 11.5% |
| IRMDIradimed | 2.3% |
| STAAStaar Surgical | −0.6% |
| Peer median | 4.9% |
Where Anika Therapeutics ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Anika Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.